| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/DMD.110.035881 |
| P8608 | Fatcat ID | release_s4okicvptrasxb6bgjgyy3wwo4 |
| P953 | full work available at URL | http://intl-dmd.aspetjournals.org/cgi/content/abstract/39/2/275 |
| https://syndication.highwire.org/content/doi/10.1124/dmd.110.035881 | ||
| P698 | PubMed publication ID | 21075975 |
| P50 | author | Pradeep Sharma | Q91186064 |
| P2093 | author name string | Michael Gillen | |
| Robert Elsby | |||
| Caroline Butters | |||
| Veronica Smith | |||
| Gemma Imisson | |||
| Dominic D. Surry | |||
| P2860 | cites work | Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues | Q24633406 |
| Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver | Q28611970 | ||
| Membrane transporters in drug development | Q29616802 | ||
| Increased drug delivery to the brain by P-glycoprotein inhibition | Q31443509 | ||
| P-Glycoprotein, a gatekeeper in the blood-brain barrier | Q33904245 | ||
| Impact of drug transporter studies on drug discovery and development | Q34215229 | ||
| Scientific perspectives on drug transporters and their role in drug interactions | Q36473986 | ||
| Drug interactions at the blood-brain barrier: fact or fantasy? | Q37362486 | ||
| An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists | Q37609641 | ||
| P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate? | Q39905120 | ||
| Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells | Q42524059 | ||
| Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate | Q42956746 | ||
| Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies | Q43213173 | ||
| Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes | Q44474943 | ||
| Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug | Q46261836 | ||
| Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments] | Q48295531 | ||
| Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux | Q60787030 | ||
| Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine | Q68692643 | ||
| Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin | Q73145730 | ||
| Relationship between high serum digoxin levels and toxicity | Q73740511 | ||
| Itraconazole decreases renal clearance of digoxin | Q74012482 | ||
| Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein | Q74180227 | ||
| A regulatory viewpoint on transporter-based drug interactions | Q94705287 | ||
| Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions | Q94705302 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug interaction | Q718753 |
| modelling biological systems | Q4299308 | ||
| P304 | page(s) | 275-282 | |
| P577 | publication date | 2010-11-12 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672 | |
| P478 | volume | 39 |
| Q38244248 | Advances in epilepsy treatment: lacosamide pharmacokinetic profile |
| Q50668713 | Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information. |
| Q37958069 | Drug-permeability and transporter assays in Caco-2 and MDCK cell lines |
| Q39062211 | MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate. |
| Q30593585 | Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I(1) ]/IC(50) and [I(2) ]/IC(50) criteria in the P-gp decision tree |
| Q50749129 | Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. |
| Q41867627 | Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination |
| Q52721223 | Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. |
Search more.